Micromet starts mid-stage trial of leukemia drug
— Micromet Inc. believed Monday it on track mid-stage trial of its mainly well ahead drug candidate, the experimental leukemia management blinatumomab.Micromet is studying the drug being a care in lieu of acute lymphoblastic leukemia. It want test blinatumomab, or else MT103, on approximately 65 adults whose pest has not responded to before behavior or else relapsed considering in the beginning flourishing behavior.The company assumed it resolve calculate how many patients accomplish complete remission and how many respond to the drug but dont hold a broad recovery of blood platelets. It plus choice compute how elongated patients respond to the drug and their survival for the duration of cure.